


OncoAlvo[®]

Genetic Study of anti-EGFR Antibody Therapy Response in Metastatic Colorectal Carcinoma

Panel Evaluation



KRAS
NRAS
BRAF
EGFR

>170 mutations
And others.



HEARTGENETICS
GENETICS & BIOTECHNOLOGY

Know more:
(+351) 231 410 896

www.heartgenetics.com

Genetic study through an informative genetic panel, scientifically validated and with proven clinic utility for the anti-EGFR Antibody Therapy Response in Colorectal Carcinoma.

OncoAlvo[®] is performed using single targeted mutation analysis through the highly accurate and innovative iPLEX MassARRAY[®] system. OncoAlvo[®] provides useful information for the treatment of metastatic Colorectal Carcinoma.

BRAF B-Raf proto-oncogene, serine/threonine kinase
EGFR Epidermal growth factor receptor
ERBB2 Erb-b2 receptor tyrosine kinase 2

KRAS KRAS proto-oncogene, GTPase
NRAS Neuroblastoma RAS viral oncogene homolog
PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha



UK NEQAS

Cancer is Personal.

So is its treatment

90-80% of patients **do not** respond to EGFR targeted therapy. Resistance mainly due to **KRAS gene** mutations & **others**.



OncoAlvo® Genetic Test

Screens all mutations recommended by the ESMO, ASCO & NICE Medical Guidelines with 99% accuracy.

Assists medical doctors in the EGFR Targeted Therapy Decision

- ✓ Analyses all mutations from medical guidelines
- ✓ Actionable decisions
- ✓ Fast turnaround times (~5 days)
- ✓ Affordable
- ✓ Robust method
- ✓ FFPE Tissue section
- ✓ 99% Sensitivity
- ✓ 99% Accuracy

Indicated to: Patients diagnosed with metastatic colon cancer

 HeartGenetics, Genetics & Biotechnology SA
Biocant Park, Núcleo D4, Lote 4A
3060-197 Cantanhede
Portugal

 contact@heartgenetics.com

 +351 231 410 896



HEARTGENETICS
GENETICS & BIOTECHNOLOGY

CENTRO 

PORTUGAL 



FINALIST  **WORLD HEALTH SUMMIT**
STARTUP TRACK 2015

Informative flyer for medical doctors

The guidelines from the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO) and the UK National Institute for Health and Care Excellence (NICE) state the RAS mutational status to be a negative predictive biomarker for therapeutic choices involving EGFR antibody therapies in the metastatic colorectal cancer, recommending for RAS testing before treatment with the EGFR-targeted monoclonal antibodies cetuximab and panitumumab.